Yazar "Ardic, Enes" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim
    Öğe
    A Case of Acute Cholestatic Hepatitis Due to Epstein-Barr Virus Infection
    (Aves, 2020) Ardic, Enes; Karaali, Rıdvan; Yağmur, Orhan; Atar, Resit Volkan; Kardan, Muhammed Enes; Doğan, Mustafa; Erdem, İlknur
    Hepatic involvement during the Epstein-Barr virus (EBV) infection is frequently seen. Elevated liver enzymes occur usually from mild to moderate. However, acute cholestatic hepatitis is a rare complication. Herein, we report a 26-year-old male with acute cholestatic hepatitis due to EBV infection.
  • Küçük Resim
    Öğe
    A rare cause of fever in an adult: a case of familial Mediterranean fever
    (Dove Medical Press Ltd, 2018) Erdem, İlknur; Saritas, Fatih; Karaali, Rıdvan; Ardic, Enes; Emeksiz, Gaye Kübra; Kara, Sonat Pınar; Bol, Oguzhan
    Background: Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease characterized by recurrent fever attacks and serositis. Nonspecific manifestations of the FMF can mimic many common acquired disorders such as infections and acute abdomen. This can delay recognition for many years and lead to comprehensive assessments and even unnecessary surgeries. Untreated FMF may lead to serious complications such as end-stage renal disease and malabsorption due to amyloid deposits in the kidneys and the digestive system. Colchicine has been used successfully to treat FMF since the 1970s. Case presentation: A 30-year-old male was admitted to our hospital with the complaints of fever, nausea, vomiting, and generalized myalgia and weakness for 15 days. The day after hospitalization, the patient had abdominal pain. Approximately a month before, the patient was treated for a diagnosis of urinary tract infection, with similar complaints. MEFV gene mutation analysis revealed homozygosity for the R202Q mutation. FMF was considered in the patient due to the presence of recurrent febrile serositis attacks and R202Q homozygous mutation in the FMF gene analyses. Colchicine was started 3x0.5 mg/day by consulting rheumatology on day 8 of admission. After the colchicine treatment, the patient's complaints markedly improved and the inflammatory markers returned to normal levels. At his follow-up visit at 6 months, the patient remained asymptomatic. Conclusion: We present a case of adult-onset FMF accompanied by peritonitis as a disease among the rare causes of fever in an adult who was treated with colchicine. Based on this case, we suggest that FMF should be kept in mind in the differential diagnosis of patients with periodic fever syndromes.
  • Küçük Resim
    Öğe
    Community-acquired Lower Urinary Tract Infections: Etiology, Antimicrobial Resistance, and Treatment Results in Female Patients
    (Wolters Kluwer Medknow Publications, 2018) Erdem, İlknur; Karaali, Rıdvan; Ardic, Enes; Omar, Şenay Elbasan; Mutlu, Reyhan; Topkaya, Aynur Eren
    Background/Purpose: Most community-acquired urinary tract infections (UTIs) are usually treated empirically. The knowledge of antibiotic resistance patterns of the microorganisms causing UTI is essential for defining the empirical treatment. Objective: The aim of the present study is to determine the distribution of bacterial strains isolated from lower UTIs and their resistance patterns against commonly used antimicrobial agents and treatment results in female patients. Subjects and Methods: This is a retrospective analysis of medical case records of 90 female patients with lower UTI for a period of 4 years from January 2013 to December 2016 in a tertiary care hospital in the Trakya region of Turkey. Results: The most common causative agent was Escherichia coli (66.6% of cases) followed by Klebsiella pneumoniae (16.6%). Fosfomycin was the most active agent against E. coli (resistant isolates: 5.5%), followed by nitrofurantoin (resistant isolates: 7.4%). Extended-spectrum beta-lactamases (ESBLs) production was observed in 29 (32.2%) isolates (22 in E. coli, 6 in K. pneumoniae, and 1 in Enterobacter spp.). The antimicrobial resistance rates among ESBL-producing E. coli isolates for trimethoprim-sulfamethoxazole, ciprofloxacin, fosfomycin, and nitrofurantoin were 77.7%, 72.7%, 13.6%, and 18.2%, respectively (P < 0.05). The estimated microbiological eradication rates for nitrofurantoin and fosfomycin were 89.7% and 83.8%, respectively. Conclusions: The results of the present study indicate that nitrofurantoin and fosfomycin may be considered for empirical therapy of lower UTIs in Trakya region of Turkey.
  • Küçük Resim Yok
    Öğe
    Retrospective Assessment of the Treatment Effectiveness of β-lactam/β-lactamase Inhibitor and Carbapenem Groups Antibiotics in Upper Urinary Tract Infections Caused by Extended Spectrum β-lactamase Producing Escherichia coli and Klebsiella Pneumoniae
    (Galenos Publ House, 2025) Ardic, Enes; Dogan, Mustafa; Kiraz, Nuri; Erdem, Ilknur
    Aim: The rate of infections caused by extended-spectrum beta-lactamase (ESBL)-producing bacteria is increasing globally. The resistance problem, which has spread especially since the 21(st) century, has led to an increase in the use of carbapenem group antibiotics in clinical cases of upper urinary tract infection (UUTI) caused by these bacteria. In this process, the increase in the number of bacteria, including carbapenemase-producing bacteria, and the slowly developing new antibiotic processes have led experts to different antibiotic therapies. In light of this situation, current evidence regarding the effectiveness of beta-lactam/beta-lactamase inhibitors (BL/BLI), which are considered an effective treatment alternative for UUTI due to ESBL-producing Enterobacterales, is still controversial. The aim of this study is to determine the effectiveness of BL/BLI versus carbapenems in the treatment of UUTI due to ESBL-producing Enterobacterales. Materials and Methods: Our study included 176 patients diagnosed with UUTI caused by ESBL-producing Escherichia coli(E. coli) and Klebsiella pneumoniae (K. pneumoniae) and treated with carbapenem or BL/BLI group antibiotics. Patients' age, gender, underlying diseases, biochemical test results, isolated microorganism and their antibiotic susceptibility, immunosuppressive therapy in the last month, accompanying bacteremia, complicating factors, having UUTI in the last year, a history of using antibiotics in the last 3 months, and a history of hospitalization admission were recorded. Results: In patient distribution, carbapenem was used in the treatment of 99(56.2%) patients and BL/BLI treatment was used in 77(43.7%) patients. The mean age of the patients was 66.81 +/- 13.82 (years), 107 (60.8%) patients were in the >= 65 age group and 88 (50%) patients were female. It was found that 79 (45%) of the patients had malignancy and 75 (42.6%) received immunosuppressive treatment. No statistically significant difference was found in clinical response and treatment outcomes (7(th), 14(th) and 30(th) day mortality) between the groups receiving specific treatment (p>0.05). Conclusion: BL/BLI (piperacillin-tazobactam) may be an effective alternative to carbapenems in the treatment of UTI due to ESBL-producing E. coli or K.pneumoniae.